'Tariff taskforce': Pharma firms scramble to prepare even as Trump levies risk flouting WTO rules
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2025
0mins
Should l Buy ?
Source: CNBC
Impact of U.S. Tariffs on European Pharmaceutical Firms: European pharmaceutical companies are forming "tariff taskforces" to prepare for potential 25% tariffs proposed by the U.S. government, which could violate World Trade Organization rules and significantly affect their operations and supply chains.
Concerns Over Domestic Manufacturing and Healthcare Costs: While some firms consider relocating production to the U.S. to mitigate costs, economists warn that such strategies may not be feasible in the short term and could lead to increased prices in the U.S. healthcare system.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
